104
Participants
Start Date
January 23, 2019
Primary Completion Date
June 8, 2020
Study Completion Date
June 8, 2020
V114
V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
Prevnar 13™
Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
Clinical Research Republica Dominicana ( Site 0401), Santo Domingo
Fundacion Dominicana de Perinatologia PRO BEBE INC ( Site 0402), Distrito Nacional
Caimed Dominicana S.A.S ( Site 0400), Santo Domingo
University of Rochester Medical Center ( Site 0105), Rochester
Ospedale San Martino ( Site 0800), Genova
Nemours/Alfred I. duPont Hospital for Children ( Site 0113), Wilmington
Children's Healthcare of Atlanta ( Site 0100), Atlanta
Cincinnati Children's Hospital Medical Center ( Site 0101), Cincinnati
Children's Hospital of Michigan ( Site 0111), Detroit
Centro de Estudios en Infectologia Pediatrica SAS ( Site 0301), Santiago de Cali
Newark Beth Israel Medical Center ( Site 0115), Newark
Santa Casa de Misericordia de Belo Horizonte ( Site 0200), Belo Horizonte
Hospital Santo Antonio - Obras Sociais Irma Dulce ( Site 0205), Salvador
Santa Casa de Misericordia de Sao Paulo ( Site 0202), São Paulo
Clinica de la Costa Ltda. ( Site 0300), Barranquilla
Agia Sophia Children s Hospital ( Site 0700), Athens
Hippokration General Hospital of Thessaloniki ( Site 0701), Thessaloniki
Cevaxin ( Site 0500), Panama City
Cevaxin ( Site 0502), Panama City
Merck Sharp & Dohme LLC
INDUSTRY